Knight Therapeutics (TSE:GUD - Get Free Report) has been given a C$9.50 price objective by investment analysts at Canaccord Genuity Group in a report released on Friday,BayStreet.CA reports. The firm currently has a "buy" rating on the stock. Canaccord Genuity Group's price objective would suggest a potential upside of 10.08% from the stock's current price.
Knight Therapeutics Stock Performance
TSE:GUD traded up C$0.28 during trading hours on Friday, reaching C$8.63. The stock had a trading volume of 155,486 shares, compared to its average volume of 95,104. The stock has a market cap of C$846.22 million, a P/E ratio of -172.60, a price-to-earnings-growth ratio of -1,013.50 and a beta of -0.21. The stock has a 50 day simple moving average of C$7.03 and a 200 day simple moving average of C$6.36. The company has a debt-to-equity ratio of 10.15, a quick ratio of 1.79 and a current ratio of 2.39. Knight Therapeutics has a 12-month low of C$5.65 and a 12-month high of C$8.70.
Knight Therapeutics (TSE:GUD - Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported C$0.13 EPS for the quarter. The firm had revenue of C$147.59 million for the quarter. Knight Therapeutics had a negative return on equity of 0.70% and a negative net margin of 1.19%. On average, research analysts forecast that Knight Therapeutics will post 0.1009486 EPS for the current fiscal year.
Knight Therapeutics Company Profile
(
Get Free Report)
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Knight Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Knight Therapeutics wasn't on the list.
While Knight Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
